Terms: = Kidney tumors AND GPC3, OCI-5, 2719, ENSG00000147257, SGBS, SGB, DGSX, SDYS, P51654, AC002420_1, SGBS1 AND Treatment
5 results:
1. Glutamine synthetase and hepatocellular carcinoma.
Jiang J; Hu Y; Fang D; Luo J
Clin Res Hepatol Gastroenterol; 2023 Dec; 47(10):102248. PubMed ID: 37979911
[TBL] [Abstract] [Full Text] [Related]
2. Attenuation of cancer proliferation by suppression of glypican-1 and its pleiotropic effects in neoplastic behavior.
Cheng F; Hansson VC; Georgolopoulos G; Mani K
Oncotarget; 2023 Mar; 14():219-235. PubMed ID: 36944188
[TBL] [Abstract] [Full Text] [Related]
3. Nanobody-based CAR T cells targeting intracellular tumor antigens.
Li H; Zhong D; Luo H; Shi W; Xie S; Qiang H; Zhu L; Gao L; Liu J; Sun S; Ding Z; Yang X; Lu X
Biomed Pharmacother; 2022 Dec; 156():113919. PubMed ID: 36411612
[TBL] [Abstract] [Full Text] [Related]
4. Glypican-3-Targeted Alpha Particle Therapy for Hepatocellular Carcinoma.
Bell MM; Gutsche NT; King AP; Baidoo KE; Kelada OJ; Choyke PL; Escorcia FE
Molecules; 2020 Dec; 26(1):. PubMed ID: 33374953
[TBL] [Abstract] [Full Text] [Related]
5. Adjuvant radiotherapy for gastric cancer: A dosimetric comparison of 3-dimensional conformal radiotherapy, tomotherapy and conventional intensity modulated radiotherapy treatment plans.
Dahele M; Skinner M; Schultz B; Cardoso M; Bell C; Ung YC
Med Dosim; 2010; 35(2):115-21. PubMed ID: 19931023
[TBL] [Abstract] [Full Text] [Related]